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Perspectives
Management of Heterotopic Ossification with Bisphosphonates 
after Hip Hemiarthroplasty in Patients with Contraindications to 
Standard of Care Prophylaxis
Peter V. TumminelW, Steven D. Shapiro^ Vanessa Cooper^, Dr. Christopher Thomas^ Dr. 
Haresh Sampathkumar\ Dr. Mohammad Islam^
'New York Medical College, Department of Physical Medicine and Rehabilitation- Metropolitan Hospital Center, 1901 1st Avenue, 
New York, NY 10029
Introduction:
Heterotopic Ossification (HO) is the production of bone outside of 
normal physiologic location on the skeleton. This is mostly caused 
by a disruption of normal bone formation, leading to production 
of bone in soft tissue. Some etiologies include, but aren’t limited to, 
surgery, neurologic injury, and genetic disease. The effects of HO 
can include functional and gait deficits, limited range of motion, and 
pain. One of the most common etiologies for the formation of HO is 
following a total hip arthroplasty (THA). The rates of HO following 
total hip arthroplasty that have been reported are variable (2-90%).'
There are methods to provide HO prophylaxis successfully via 
NSAIDs, single dose radiation therapy, or combination therapy.^’^ 
However, there are no alternative therapies for HO prophylaxis for 
patients with contraindications to NSAIDs and radiation therapy. 
This report seeks to suggest methods to prevent HO outside stan­
dard of care therapies for this subset of patients.
Case Description:
Figure T. Pre-operative left hip radiograph- transcervi- 
cal neck fracture of femur.
One month post left hip hemiarthroplasty, a 78-year-old Jehovah 
Witness man with history of diabetes, hypertension, chronic kidney 
disease, anemia, and thrombocytopenia presented with functional 
and gait deficits. The patient had sustained femoral neck fracture 
after a fall at home secondary to hypertensive encephalopathy. Left 
hip X-ray revealed a femoral neck fracture. The patient received a 
left total hip arthroplasty, and was subsequently admitted to acute 
inpatient rehabilitation.
The patient developed intolerable pain three weeks after his admis­
sion to inpatient rehabilitation, and he became non-weight bearing 
on his left leg. Prior to this development the patient was able to walk 
25-30 feet in therapy. Repeat X-rays were negative. CT without con­
trast was performed on the hip at that time which demonstrated left 
sided prosthesis with no loosening. The CT also showed scattered 
areas of bone formation seen in the soft tissue at the inner and outer 
margin of the hip. Heterotopic bone formation was also noted in­
volving the piriformis, gemelli muscles, obturator internus, quadra- 
tus femorus, distal insertion of the iliopsoas, and gluteus maximus.
Figure 2: Post-operative radiograph of left total hip 
arthroplasty.
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Figure 3: Degree of HO three weeks after admission 
to acute inpatient rehabilitation (X-ray).
Discussion:
This patient’s symptoms of progressive functional and gait 
disturbance due to pain are consistent with HO as demon­
strated by CT. The patient was unable to receive NSAIDs for 
prophylaxis due to a past medical history of chronic kidney 
disease. In addition, the patient had not received radiation 
therapy in the recommended perioperative period from 24 
hours prior to surgery to 72 hours post-op. The patient’s 
past medical history of anemia and thrombocytopenia were 
also contraindications to radiation therapy. The patient’s 
thrombocytopenia was also a contraindication to low dose 
aspirin therapy.
A literature review study had looked into evidence of alter­
native therapies for heterotopic ossification prophylaxis and 
treatment using a modified Sackett Scale.
Treatment
Bisphosphonate studies show cohort study Level 2 evidence 
in the treatment of HO if the diagnosis is made early (3-6 
weeks post-op). Bisphosphonates, however, are unlikely to 
be a^ effective if treatment is started when radiographs are 
positive. There is also a case series Level 4 evidence that bi­
sphosphonates stops secondary HO after surgical resection 
ofHO.=
Another study was done to assess the potential benefits and 
adverse effects of bisphosphonates in CKD patients with 
osteoporosis. Results showed that nephrotoxicity and drug 
accumulation is uncommon and of little clinical significance 
when lower doses of bisphosphonates are used in CKD. It 
was demonstrated that bisphosphonates were safe as long as 
renal function was closely monitored with administration 
in Stage 1-3 CKD for osteoporotic patients.® If bisphospho­
nates can be safely used in CKD patients with osteoporosis.
Figure 4: Degree of HO three weeks after admission to 
acute inpatient rehabilitation (CT).
there may be a safe way to administer bisphosphonates in 
patients with mild-moderate CKD to treat HO.
A retrospective study was performed in which the man­
agement of five cases with bisphosphonate therapy after 
surgical excision of primary HO had prevented the need for 
a second surgery. No recurrences were seen in this small 
study. Furthermore, none of the patients had side effects 
including nephrotoxicity. It is suggested that the bisphos­
phonates not only inhibit the mevalonate pathway in 
osteoclasts, but also act as an anti-inflammatory by inter­
acting with IL-1, IL-6, and TNF.^ The exact mechanism of 
HO prevention is unknown, but correlations exist such that 
more research should be done with larger sample sizes to 
demonstrate the efficacy of bisphosphonates for HO pro­
phylaxis and treatment.
Treatment Plan:
The primary treatment plan in place for this patient was 
conservative management. The patient was placed on 
passive ROM therapy without additional prophylaxis or 
treatment. The use of passive ROM therapy remains con­
troversial. Some studies suggest that passive ROM therapy 
may increase the incidence of HO due to microtraumas. 
However, other studies emphasize the significance of ROM 
exercise to maintain mobility and function. A study by Gar­
land demonstrated that 64% of affected joints maintained 
or gained ROM with joint manipulation and passive ROM 
therapy®. The risk/benefit ratio of joint manipulation favors 
joint manipulation in patients for HO prophylaxis.
Conclusion:
Heterotopic ossification is a complication that causes 
decrease in extremity range of motion and an increase in 
patient pain after trauma, neurological injury, or genetic
9
Perspectives
disease. Although there are few alternative therapies for 
HO prophylaxis and treatment, these studies show some 
promise for subsets of patients who have contraindications 
to NSAID and radiation therapy. More research is needed 
to assess the benefits of these alternative treatments within 
therapeutic windows to assess toxicity and adverse effects.
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